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Objectives: This study aims to understand unmet medical needs despite 
available treatment options of venous thromboembolism (VTE) treatment in 
Europe. MethOds: This retrospective cohort study included data from physi-
cians (376 general practitioners and 307 specialists) in France, Germany, Italy, 
and Spain, who completed case report forms for the next 3-4 patients seen in 
consultation meeting inclusion criteria. Patients were assigned to mutually 
exclusive groups based on a hierarchy (vitamin K antagonist (VKA), rivaroxa-
ban, low-molecular-weight-heparin (LMWH), aspirin, other anti-coagulants, no 
known treatment, respectively) determined by treatment data (dosing, start/end 
dates, and prescription duration and prescriber information, either in hospital 
or at discharge, following VTE, or as new treatment for first-time VTE event). 
Logistic regression with backward elimination identified significant predictors 
of treatment allocation. Results: Patients’ mean age (total n= 2184) was 61.3 
years (SD= 14.3) and 47.4% were females. The hierarchy of treatments revealed 
that 63.1% of patients were using VKA, 30.6% using rivaroxaban or LMWH but no 
VKA, and 6.2% using other combinations. Mean treatment period was higher for 
VKA (168 days) than for rivaroxaban (139 days) or LMWH (46 days) patients. LMWH 
treatment was significantly more common than VKA among cancer patients (odds 
ratio (OR):2.35, P< .001), but less likely among pulmonary embolism or deep vein 
thrombosis patients with (OR:0.35, P= .001) or without complications (OR:0.33, 
P= .001), hospitalization for first VTE (OR:0.32, P< .001), and hip/knee replacement 
(OR:0.39, P= .028). Predictors of VKA vs. rivaroxaban included: more months since 
initial VTE event (OR:1.06, P< .001), no hormone replacement therapy (OR:5.83, 
P< .001), no chronic heart failure (OR:2.09, P= .001), and age of 40+ (OR:1.61, 
P= .03). cOnclusiOns: Treatment patterns in the European Union show that VKA 
is a common treatment for VTE in addition to other anticoagulants. Attention to 
risk factors can play a major role in determining continuation of therapy which 
is likely to reduce VTE recurrence.
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Objectives: A signal of bisphosphonate-related cardiac valve calcification lead-
ing to cardiac valve insufficiency was detected in the European adverse event 
monitoring system (EudraVigilance); however no signal detection activity was 
conducted in the US. This pharmacovigilance analysis investigates and relation-
ship between bisphosphonates and aortic and mitral valve calcification in the FDA 
Adverse Event Reporting System (FAERS). MethOds: Bisphosphonate-related 
adverse event reports submitted to FAERS between 1997 and 2013 were used to 
investigate the disproportional reporting of cardiac valve disorders (CVD) in rela-
tion to bisphosphonates therapy, including aortic and mitral valve calcification. 
Multi-item Gamma Poisson Shrinker data mining algorithm was used to calculate 
Empirical Bayes Geometric Mean (EBGM) and corresponding 95% confidence interval 
as disproportionality measures. Signals that warrant further review are defined 
as measures with confidence interval lower limit≥ 2.0. The Anatomical Chemical 
and Therapeutic classification was used to define bisphosphonate exposure, and 
the Medical Dictionary for Regulatory Activities, Preferred Term coding hierar-
chy was used to define cardiac valve calcification. Results: A total of 2,010 CVD 
events were submitted for bisphosphonates. Of those, 116 events were for cardiac 
valve calcification, affecting aortic valve (n= 32); mitral valve (n= 83); and pulmo-
nary valve (n= 1). Signals were detected for alendronate (aortic: n= 8, EBGM= 3.7, 
95%CI= 2.03-6.34; mitral: n= 15, EBGM= 3.99, 95%CI= 2.58-5.96); pamidronate (aortic: 
n= 7, EBGM= 9.94, 95%CI= 3.27-30.3; mitral: n= 25, EBGM= 36.8, 95%CI= 26.1-50.6); and 
Zoledronate (aortic: n= 13, EBGM= 4.44, 95%CI= 2.77-6.86; mitral: n= 39, EBGM= 7.23, 
95%CI= 5.45-9.58). No signal was detected for ibadronate (aortic: n= 1, EBGM= 0.92, 
95%CI= 0.21-2.92; mitral: n= 2, EBGM= 1.02, 95%CI= 0.32-2.58) and risedronate (aor-
tic: n= 3, EBGM= 2.6, 95%CI= 0.99-5.9; mitral: n= 2, EBGM= 1.43, 95%CI= 0.45-3.61; pul-
monary: n= 1, EBGM= 1.36, 95%CI= 0.3-4.38). cOnclusiOns: Treatment with some 
bisphosphonates might be associated with aortic and mitral valve calcification. It 
might be necessary for prescribers to monitor patients for CVD before and periodi-
cally during bisphosphonates therapy. Signal clarification and evaluation activities 
by pharmacoepidemiologic studies are recommended.
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Objectives: The aim of this network meta-analysis was to compare the safety of 
tofacitinib to biological DMARDs for treatment of rheumatoid arthritis in patient 
with inadequate response to methotrexate. MethOds: We performed an overview 
of systematic reviews that evaluated biological DMARDs or tofacitinib for treat-
ment of rheumatoid arthritis patients with inadequate response to methotrexate. 
The searching was carried out using the database of MEDLINE, EMBASE, Lilacs, 
COCHRANE, DARE and HTA restrictive to systematic review published in the last 
five years. The strategy of search was the similar to guideline of rheumatoid arthritis 
of the Ministry of Health of Colombia. Two researchers selected independently the 
studies and extracted the data. La risk of bias of systematic review was assessed 
with AMSTAR and ISPOR tools. The clinical trials were evaluated with The Cochrane 
Collaboration’s tool for assessing risk of bias . Bayesian mixed treatment compari-
son method was applied for the pairwise comparison of treatments, where the 
common comparator was methotrexate. The outcomes were occurrence of serious 
adverse events, serious infections and withdrawal due to adverse event. Results: 
treatment initiation. The rates of TM were significantly different across ADCs; 
angiotensin converting enzyme inhibitor and angiotensin receptor blocker users 
were less likely to receive TMs compared to other drug classes. The mean time-
to-TM was > 100 days for patients adding or uptitrating medications, and > 150 
days for those switching or downtitrating medications. The likelihood of discon-
tinuation was significantly lower for patients intensifying treatment by adding 
medications vs. those uptitrating dose (HR= 0.765; CI: 0.701-0.834). cOnclusiOns: 
TMs are common among newly treated hypertensive patients. The rates of TM 
vary significantly across ADCs. In the real-world, TMs occur much later than the 
30-day time-line recommended by clinical guidelines. Addition of drugs may be a 
preferred approach vs. uptitrating drug dose for intensifying treatment of patients 
who are at a high risk of treatment discontinuation.
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Objectives: objective: Despite the efficacy and safety of statins, real-world data 
suggest they are suboptimally used among dyslipidemic patients. The current 
study sought to describe patterns of statin utilization among high cardiovascular 
(CV)-risk patients initiating statin therapy. MethOd: Methods: Adult patients (≥ 18 
years) with continuous enrollment who were newly initiating statins were identi-
fied from the Truven MarketScan Research databases (01/2007-06/2013). Patients 
were selected for and stratified into 1 of 5 mutually exclusive, high CV-risk–based 
hierarchical categories: recent acute CV event ( hospitalization for acute coronary 
syndrome [ACS] or other CV event within 90 days of index), coronary heart disease 
(CHD), ischemic stroke, peripheral vascular disease/peripheral artery disease (PVD/
PAD), and diabetes. Descriptive statistics and time-to-event analyses were used to 
measure proportion of days covered (PDC), time to discontinuation, and hospitaliza-
tion rates. Results: results: Among 541,221 high CV-risk patients, 61% were in the 
diabetes cohort, followed by recent acute CV event (26%), PVD/PAD (5%), CHD (4%), 
and ischemic stroke (4%). High-intensity statins (atorvastatin 40/80 mg, rosuvastatin 
20/40 mg, simvastatin 80 mg) were initiated in 15% of patients, with the percentages 
varying among subgroups (10% [diabetes] to 31% [ACS]). More than 20% of high-
intensity statin initiators switched to a moderate- to low-intensity statin (range, 
19% [PVD/PAD] to 28% [other CV event]). The PDC ranged from 56% (diabetes) to 
66% (ACS). Median time to statin discontinuation among high CV-risk patients was 
approximately 15 months. Median time to discontinuation among patients receiv-
ing high-intensity versus moderate- to low-intensity statin was 21 months and 15 
months, respectively. At 1 year, Kaplan-Meier estimates of cumulative event rates 
for CV-related hospitalizations were lowest in the diabetes cohort and highest for 
patients with recent ACS hospitalization (4% and 22%, respectively). cOnclusiOns: 
conclusion: Low PDC and discontinuation of statin therapy were observed among 
high CV-risk patients. Interventional opportunities to ensure better therapy man-
agement are warranted.
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Objectives: In patients with spontaneous intracerebral hemorrhage (ICH), cur-
rent guidelines recommend managing elevated blood pressure (BP) with inter-
mittent or continuous infusion of intravenous medications. The purpose of this 
retrospective observational study is to evaluate the clevidipine (CLV) usage pat-
terns and patient outcomes of continuous infusion intravenous antihyperten-
sive agents (IVAH) compared to other agents available. MethOds: Study data 
were extracted from the Premier hospital database. ICH patients were identified 
by primary diagnosis ICD-9 CM codes of 431 (ICH) or 432 (other or unspecified 
ICH) and a final MS-DRG of 64, 65, 66 (Intracranial hemorrhage or cerebral infarc-
tion). Patients who received clevidipine, nicardipine, or nitroprusside during the 
first two days of admission between January 2009 and June 2014 were included. 
Baseline demographics, outcomes, and costs were evaluated and propensity score 
matching comparing CLV to nicardipine (NIC) and CLV to nitroprusside (SNP) was 
performed to control for confounders. Results: 165 clevidipine, 15910 nicardi-
pine, and 1091 nitroprusside inpatients from 520 US hospitals met the inclusion 
criteria. Treatment pattern analysis showed nitroprusside usage decreased from 
15.8% in 2009 to 1.3% in 2014, while NIC and CLV usage increased over the same 
time; CLV from 0.8% to 2.7% . After propensity matching, 126 patients remained 
in each group for the CLV-NIC pair and 90 patients in the CLV-SNP pair. Mortality 
rates were similar in both comparisons at 27.8% (CLV) vs 28.6% (NIC) and 31.1% 
(CLV) vs. 37.8% (SNP). After excluding in-hospital deaths, mean length of stay 
was 7.8 days (CLV) vs 8.8 days (NIC) and 8.0 days (CLV) vs 8.2 days (SNP). Inflation 
adjusted mean total costs were $16903 (CLV) vs $18634 (NIC) and $15972 (CLV) vs 
$15965 (SNP). cOnclusiOns: Although CLV is < 3% of use in this sample, PSM 
demonstrates similar outcomes in comparison with NIC and SNP.
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